Consistency of protocol and safety data reporting in clinical trial registrations and corresponding publications of interventions involving MDMA and psilocybin.
Journal of Clinical Epidemiology January 23, 2026 Marija Franka Žuljević, Antonija Mijatović, Renata Orhanović et al. 4 citations
MDMA and psilocybin are being investigated as potential treatments for psychiatric disorders and have received increasing regulatory and media attention, due to the methodological complexities and societal context of psychedelic substances. Therefore, we assessed the consistency of protocol registration and adverse event (AE) reporting in clinical trials of MDMA and psilocybin. We conducted a...